• Postgraduate medicine · May 2022

    Use of zoledronic acid in antiosteoporosis treatment is associated with a decreased blood lipid level in postmenopausal women with osteoporosis: A cohort study in China.

    • Wei Luo, Jin Zhang, Ling Xu, Yao Zhou, Dan Xu, Qiuju Lv, Yi Xiao, and Qin Yang.
    • Department of Endocrinology, People's Hospital of Leshan, Leshan City, Sichuan Province, China.
    • Postgrad Med. 2022 May 1; 134 (4): 406-412.

    ObjectiveThis cohort study aimed to evaluate the protective effects of zoledronic acid (ZA) in lipidemia in postmenopausal women with osteoporosis.MethodsA total of 668 postmenopausal women with osteoporosis were regularly followed up for 12 months between January 2018 and August 2021 in the department of endocrinology and the health examination center of the hospital. They were divided into group I and group II depending on lipid metabolism disorder; Group II received atorvastatin 20 mg/d orally. Groups I and II were divided into experimental group (ZA exposure) and control group (ZA nonexposure).ResultsIn group I, which was the ZA exposure group, the level of low-density lipoprotein cholesterol (LDL-C) was significantly lower than that before ZA treatment (P = 0.017); in the ZA nonexposure group, the levels of LDL-C, total cholesterol (TC), and triglycerides (TG) significantly increased after 12 months of follow-up (P = 0.005, P < 0.001, and P = 0.001). At the baseline, no significant difference was found in blood lipid indicators between the ZA exposure and nonexposure groups (P > 0.05), but the levels of LDL-C and TC in the exposed group significantly decreased after 12 months of follow-up (P = 0.008 and P = 0.027).  In group II, which was the ZA exposure group, the levels of LDL-C and TC were significantly lower than those before ZA treatment (P < 0.001 and P < 0.001). At the baseline, the ZA exposure and nonexposure groups had no significant difference in blood lipid indicators (P > 0.05), but the levels of LDL-C and TC significantly decreased in the exposed group after 12 months of follow-up (P < 0.001 and P = 0.003).ConclusionThis cohort study found that ZA might exert a protective effect on lipid metabolism in postmenopausal women with osteoporosis. In postmenopausal women with lipid disorders suffering from osteoporosis, the treatment with ZA combined with atorvastatin significantly reduced the level of blood lipid compared with atorvastatin alone.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…